Breast Cancer Clinical Trials

• Female with age ≥ 18 years,

• Patients with previously untreated, non-metastatic, centrally confirmed TNBC for whom a neoadjuvant treatment with chemotherapy + pembrolizumab is the recommended option as standard of care,

• Patients with measurable targets according to RECIST/PERCIST criteria,

• Patients without distant metastasis based on staging 18F-FDG PET/CT,

• Patients with tumor tissue available,

• Patients who provided a signed written informed consent,

• Patient ability to comply with protocol requirements,

• Patients covered by a health insurance system.